The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on α7 nicotinic receptors in hippocampal neurons: Clinical implications for treatment of Alzheimer's disease

Journal of Molecular Neuroscience

Volumn 30, Issue 1-2, 2006, Pages 227-232

  Popa, Rodica V ^a   Pereira, Edna F R ^a   Lopes, Cristiane ^a   Maelicke, Alfred ^a,b   Albuquerque, Edson X ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Galantos Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUNGAROTOXIN RECEPTOR; CARBAMIC ACID DERIVATIVE; GALANTAMINE;

ALLOSTERISM; ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HIPPOCAMPUS; NERVE CELL; NERVE CELL CULTURE; NONHUMAN; RAT;

ANIMALS; CELL CULTURE TECHNIQUES; CHOLINE; EVOKED POTENTIALS; GALANTAMINE; HIPPOCAMPUS; LIGANDS; NEURONS; PATCH-CLAMP TECHNIQUES; RECEPTORS, NICOTINIC;

EID: 33845922830     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:30:1:227     Document Type: Conference Paper

References (26)

1. Aracava Y., Pereira E. F. R., Maelicke A., and Albuquerque E. X. (2005) Memantine blocks α7* nicotinic acetylcholine receptors more potently than NMDA receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 313, 1195-1205.
2. Arias E., Ales E., Gabilan N. H., et al. (2004) Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46, 103-114.
3. Bachus R., Bickel U., Thomsen T., Roots I., and Kewitz H. (1999) The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 9, 661-668.
4. Bickel U., Thomsen T., Weber W., et al. (1991) Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin. Pharmacol. Ther. 50, 420-428.
5. Capsoni S., Giannotta S., and Cattaneo A. (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. U. S. A. 99, 12,432-12,437.
6. Carlson N. G., Bacchi A., Rogers S. W., and Gahring L. C. (1998) Nicotine blocks TNF-alpha-mediated neuroprotection to NMDA by an alpha-bungarotoxin- sensitive pathway. J. Neurobiol. 35, 29-36.
7. Chung J. A. and Cummings J. L. (2000) Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol. Clin. 18, 829-846.
8. Corey-Bloom J. (2003) Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int. J. Clin. Pract. 57, 219-223.
9. Ferri C. P., Prince M., Brayne C., et al. Alzheimer's Disease International. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.
10. Han S. Y., Sweeney J. E., Bachman E. S., et al. (1992) Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatices. A potential application in Alzheimer's disease? Eur. J. Med. Chem. 27, 673-687.
11. Hejmadi M. V., Dajas-Bailador F., Barns S. M., Jones B., and Wonnacott S. (2003) Neuroprotection by nicotine against hypoxia-induced apoptosis in cortical cultures involves activation of multiple nicotinic acetylcholine receptor subtypes. Mol. Cell. Neurosci. 24, 779-786.
12. Hellström-Lindahl E., Mousavi M., Zhang X., Ravid R., and Nordberg A. (1999) Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res. Mol. Brain Res. 66, 94-103.
13. Kihara T., Shimohama S., Sawada H., et al. (1997) Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann. Neurol. 42, 159-163.
14. Levin E. D., McClernon F. J., and Rezvani A.H. (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl.) 184, 523-539.
15. Maelicke A. and Albuquerque E .X. (1996) New approach to drug therapy of Alzheimer's dementia. Drugs Dis. Today 1, 53-59.
16. Mihailova D., Yamboliev I., Zhivkova Z., Tencheva J., and Jovovich V. (1989) Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 39, 50-58.
17. Nakamizo T., Kawamata J., Yamashita H., et al. (2005) Stimulation of nicotinic acetylcholine receptors protects motor neurons. Biochem. Biophys. Res. Commun. 330, 1285-1289.
18. Nordberg A. (2001) Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol. Psychiatry 49, 200-210.
19. Pereira E. F. R., Hilmas C., Santos M. D., Alkondon M., Maelicke A., and Albuquerque E.X. (2002) Unconventional ligands and modulators of nicotinic receptors. J. Neurobiol. 53, 479-500.
20. Perry E. K., Martin-Ruiz C. M., and Court J. A. (2001) Nicotinic receptor subtypes in human brain related to aging and dementia. Alcohol 24, 63-68.
21. Sabbagh M. N., Reid R. T., Hansen L. A., Alford M., and Thal L. J. (2001) Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies. J. Neural Transm. 108, 1149-1157.
22. Sweeney J. E., Bachman E. S., and Coyle J. T. (1990) Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology (Berl.) 102, 191-200.
23. Thomsen T., Kaden B., Fischer J. P., et al. (1991) Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur. J. Clin. Chem. Clin. Biochem. 29, 487-492.
24. Wevers A., Monteggia L., Nowacki S., et al. (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur. J. Neurosci. 11, 2551-2565.
25. Woodruff-Pak D. S. (2001) Eyeblink classical conditioning differentiates normal aging from Alzheimer's disease. Integr. Physiol. Behav. Sci. 36, 87-108.
26. Zhang Z. W., Coggan J. S., and Berg D. K. (1996) Synaptic currents generated by neuronal acetylcholine receptors sensitive to alpha-bungarotoxin. Neuron 17, 1231-1240.